Education
About Us
Working with TipRanks
Follow Us
Aclaris Therapeutics (ACRS)
NASDAQ:ACRS
ACRS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.95 - $5.17
Previous CloseN/A
Volume227.82K
Average Volume (3M)980.97K
Market Cap
$159.72M
Enterprise Value$125.36M
Total Cash (Recent Filing)$10.76M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.75
Next Earnings
May 13, 2025EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.51
Shares Outstanding107,918,820
10 Day Avg. Volume999,867
30 Day Avg. Volume980,969
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)9.22
Price to Cash Flow (P/CF)-4.80
P/FCF Ratio0.00
Enterprise Value/Market Cap0.78
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit7.87
Enterprise Value/Ebitda-2.41
Forecast
1Y Price Target
$9.25Price Target Upside500.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Aclaris Therapeutics News
PremiumCompany Announcements
Aclaris Therapeutics Reports 2024 Financial Results
PremiumPre-Earnings
Is ACRS a Buy, Before Earnings?---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsBSI-045B showed promising results in a Phase 2a study for atopic dermatitis, with high efficacy rates compared to currently approved therapies.
Financial PerformanceAclaris announced an $80M PIPE financing, indicating strong financial backing for its pipeline developments.
Pipeline DevelopmentThe company has strengthened its immunology-focused pipeline with two in-licensed biologics, signaling further growth and innovation.
Bears Say
CompetitionBSI-045B is believed to be differentiated from competitors due to its extended residence time, high binding affinity, and promising pharmacological activity.
---
Ownership Overview
29.40% Insiders
4.88% Mutual Funds
0.42% Other Institutional Investors
59.43% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ACRS FAQ
What was Aclaris Therapeutics’s price range in the past 12 months?
Aclaris Therapeutics lowest stock price was $0.95 and its highest was $5.17 in the past 12 months.
What is Aclaris Therapeutics’s market cap?
Aclaris Therapeutics’s market cap is $159.72M.
When is Aclaris Therapeutics’s upcoming earnings report date?
Aclaris Therapeutics’s upcoming earnings report date is May 13, 2025 which is in 39 days.
How were Aclaris Therapeutics’s earnings last quarter?
Aclaris Therapeutics released its earnings results on Feb 27, 2025. The company reported -$1.01 earnings per share for the quarter, missing the consensus estimate of -$0.287 by -$0.723.
Is Aclaris Therapeutics overvalued?
According to Wall Street analysts Aclaris Therapeutics’s price is currently Undervalued.
Does Aclaris Therapeutics pay dividends?
Aclaris Therapeutics does not currently pay dividends.
What is Aclaris Therapeutics’s EPS estimate?
Aclaris Therapeutics’s EPS estimate is -0.14.
How many shares outstanding does Aclaris Therapeutics have?
Aclaris Therapeutics has 107,918,820 shares outstanding.
What happened to Aclaris Therapeutics’s price movement after its last earnings report?
Aclaris Therapeutics reported an EPS of -$1.01 in its last earnings report, missing expectations of -$0.287. Following the earnings report the stock price went down -7.143%.
Which hedge fund is a major shareholder of Aclaris Therapeutics?
Currently, no hedge funds are holding shares in ACRS
---
Aclaris Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.25 (500.65% Upside)
$9.25 (500.65% Upside)
Hedge Fund Trend
Increased
By 4.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 4.4%
Last 30 Days ▼ 4.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
26.22%
12-Months-Change
Fundamentals
Return on Equity
-84.46%
Trailing 12-Months
Asset Growth
10.41%
Trailing 12-Months
Company Description
Aclaris Therapeutics
Aclaris Therapeutics, Inc. is a biopharmaceutical company that operates in the healthcare sector, focusing on the development and commercialization of innovative therapies for dermatological and immuno-inflammatory diseases. The company is engaged in the research and development of small molecule therapies that aim to address significant unmet medical needs. Aclaris's core products include drug candidates targeting specific enzymes and pathways relevant to dermatological conditions, such as alopecia areata and vitiligo.
---
ACRS Stock 12 Month Forecast
Average Price Target
$9.25
▲(500.65% Upside)
Technical Analysis
Protara Therapeutics
―
Innate Pharma
―
4D Molecular Therapeutics
―
TriSalus Life Sciences
―
Molecular Partners
―
Best Analysts Covering ACRS
1 Year
1 Year Success Rate
2/11 ratings generated profit
1 Year Average Return
-36.65%
reiterated a buy rating 4 months ago
Copying Roger Song's trades and holding each position for 1 Year would result in 18.18% of your transactions generating a profit, with an average return of -36.65% per trade.
---